Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytarabine + thiotepa + fludarabine + busulfan
- Development stage
- Phase 2
- Lead developer
- Adienne S.r.l. S.U.
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A myeloablative conditioning regimen used before allogeneic stem cell transplantation, particularly for patients with acute myeloid leukemia (AML). This combination has demonstrated promising outcomes in cord blood and haploidentical stem cell transplantation. The regimen provides significant anti-leukemic effects with thiotepa and busulfan having good penetration into the central nervous system. Studies have shown that this regimen provides lower relapse rates compared to other conditioning regimens like busulfan plus cyclophosphamide (BuCy), while maintaining similar survival outcomes.
02
Targets
DNADNA polymerase familydsDNA (Double-stranded DNA)
Beyond the preview
Go deeper on cytarabine + thiotepa + fludarabine + busulfan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytarabine + thiotepa + fludarabine + busulfan.